Folic acid deficiency: Main etiological factor of megaloblastic anemia in Kazakhstan?

✍ Scribed by Ainur Akilzhanova; Noboru Takamura; Kiyoshi Aoyagi; Ludmila Karazhanova; Shunichi Yamashita

• Book ID: 101437444
• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 285 KB
• Volume: 81
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/ajh.20576

✦ Synopsis

Induction Chemotherapy and Post-Remission Imatinib Therapy for de Novo BCR-ABL-Positive AML

To the Editor: Translocation t(9;22)(q34;q11) is found in 1-2% of newly diagnosed patients with de novo AML. The prognosis of Ph þ AML is very poor with a median survival time of only 7 months. We present two patients with de novo Ph þ AML who received induction chemotherapy and post-remission imatinib therapy.

A 73-year-old man was admitted in November 2003 with fatigue and palpitation. Physical examination showed only pallor. The Hb was 83 g/L, platelets 145 Â 10 9 /L, and WBC 1.4 Â 10 9 /L, 0.12 Â 10 9 /L blast cells. FACS analysis of marrow mononuclear cells showed 22% blast cells positive for HLA-DR, CD34, CD117, CD13, CD33, MPO, and CD38 and partially CD11b. Karyotype analysis of bone